Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 17;84(3):22br14567.
doi: 10.4088/JCP.22br14567.

Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder

Zhenhao Shi  1   2 , Xinyi Li  1 , Kyle M Kampman  1 , Anna Rose Childress  1 , Corinde E Wiers  1 , Daniel D Langleben  1
Affiliations

Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder

Zhenhao Shi et al. J Clin Psychiatry. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Correlation between BDI score and change in cue-induced opioid craving. (B) Correlation between BDI score and change in NAcc drug cue-reactivity. The anatomically defined NAcc region of interest (red) is shown at y=10 in the Montreal Neurological Institute (MNI) space. The grey-shaded areas represent 95% confidence intervals. Abbreviations: BDI, Beck Depression Inventory; NAcc, nucleus accumbens.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Courtney KE, Schacht JP, Hutchison K, Roche DJO, Ray LA. Neural substrates of cue reactivity: association with treatment outcomes and relapse. Addict Biol 2016;21(1):3–22. - PMC - PubMed
    1. Li Q, Li W, Wang H, et al. Predicting subsequent relapse by drug-related cue-induced brain activation in heroin addiction: an event-related functional magnetic resonance imaging study. Addict Biol 2015;20(5):968–978. - PubMed
    1. Shi Z, Jagannathan K, Padley JH, et al. The role of withdrawal in mesocorticolimbic drug cue reactivity in opioid use disorder. Addict Biol 2021;26(4):e12977. - PubMed
    1. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011;377(9776):1506–1513. - PubMed
    1. Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction 2013;108(9):1628–1637. - PubMed

Publication types

MeSH terms